Marc-Andre Kasper

Company: Tubulis GmbH

Job title: Vice President - Chemistry & Early Discovery

Seminars:

Technology for Degrader-Antibody Conjugates to Unlock Heterobifunctional Degraders Through mAb-like Pharmacokinetics & Excellent in vivo Efficacy 2:30 pm

Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors Exploring novel conjugation technologies for stable conjugation and traceless release of heterobifunctional degraders Resulting DACs are homogenous with at high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacyRead more

day: Day Two